Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma Getting the right treatment to the right patient remains the holy grail of oncology. Adding ...
Author: Dr. Sean Kelly, MD, Chief Medical Officer and VP Customer Strategy, Healthcare at Imprivata and Attending physician, Beth Israel Lahey Health, Assistant Professor of Emergency Medicine, ...
Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer and residual disease after neoadjuvant therapy are at high risk for recurrence. In a phase 3, open-label, ...
Trastuzumab deruxtecan has shown efficacy in patients with previously treated human epidermal growth factor receptor 2 (HER2)–positive advanced or metastatic breast cancer. The efficacy and safety of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results